









Markets
/
Stocks
/
nasdaq-ccel
/

Cryo-Cell International Inc

CCEL

3.380USD

+0.010+0.30%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

27.23MMarket Cap

LossP/E TTM



Cryo-Cell International Inc

3.380

+0.010+0.30%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cryo-Cell International Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cryo-Cell International Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 8.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cryo-Cell International Inc's Score

Industry at a Glance

Industry Ranking

58 / 75

Overall Ranking

297 / 4521

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Cryo-Cell International Inc Highlights

StrengthsRisks

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Growing

The company is in a growing phase, with the latest annual income totaling USD 31.99M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -60.02, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 150.99K shares of this stock.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

8.500

Target Price

+86.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cryo-Cell International Inc is 8.20, ranking 31 out of 75 in the Healthcare Providers & Services industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 7.83M, representing a year-over-year decrease of 2.99%, while its net profit experienced a year-over-year decrease of 28.74%.

Score

Industry at a Glance

Previous score

8.20

Change



Financials

4.88

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.97

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.42

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.74

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cryo-Cell International Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cryo-Cell International Inc is 6.10, ranking 60 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -60.02, which is -862.97% below the recent high of 457.97 and -371.08% above the recent low of -282.77.

Score

Industry at a Glance

Previous score

6.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 58/75

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cryo-Cell International Inc is 6.00, ranking 62 out of 75 in the Healthcare Providers & Services industry. The average price target is 8.50, with a high of 8.50 and a low of 8.50.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

8.500

Target Price

+86.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Cryo-Cell International Inc

CCEL

CVS Health Corp

CVS

Teladoc Health Inc

TDOC

HCA Healthcare Inc

HCA

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cryo-Cell International Inc is 6.01, ranking 65 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 3.65 and the support level at 3.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.12

Change

-0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.026

Neutral

RSI(14)

42.806

Neutral

STOCH(KDJ)(9,3,3)

37.156

Neutral

ATR(14)

0.165

High Vlolatility

CCI(14)

-24.375

Neutral

Williams %R

66.658

Sell

TRIX(12,20)

-0.267

Sell

StochRSI(14)

82.425

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.376

Buy

MA10

3.394

Sell

MA20

3.409

Sell

MA50

3.634

Sell

MA100

4.035

Sell

MA200

4.478

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cryo-Cell International Inc is 3.00, ranking 60 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 13.06%, representing a quarter-over-quarter increase of 0.08%. The largest institutional shareholder is The Vanguard, holding a total of 150.99K shares, representing 1.87% of shares outstanding, with 28.14% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Portnoy (David I)

1.70M

+0.93%

Portnoy (Mark)

935.77K

Fleishman (Adam)

509.00K

Hamilton Lane Advisors, LLC

409.73K

SFI Advisors LLC

165.30K

The Vanguard Group, Inc.

Star Investors

150.99K

+16.31%

The MassMutual Trust Company, FSB

111.03K

Mikulinsky (Oleg)

104.35K

Berger (Harold D)

57.90K

Geode Capital Management, L.L.C.

53.42K

+16.55%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cryo-Cell International Inc is 2.80, ranking 61 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.